Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combating Alzheimer’s and Parkinson’s Disease with Novel Antibodies

05.12.2012
Novel Antibodies for Combating Alzheimer’s and Parkinson’s Disease

Researchers at Rensselaer Polytechnic Institute Develop Antibodies With Improved Ability for Preventing Formation of Toxic Protein Particles Linked to Diseases Including Alzheimer’s and Parkinson’s

Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer’s disease and Parkinson’s disease, as well as Type 2 diabetes, according to a new study.

The onset of these devastating diseases is associated with the inappropriate clumping of proteins into particles that are harmful to cells in the brain (Alzheimer’s disease and Parkinson’s disease) and pancreas (Type 2 diabetes). Antibodies, which are commonly used by the immune system to target foreign invaders such as bacteria and viruses, are promising weapons for preventing the formation of toxic protein particles. A limitation of conventional antibodies, however, is that high concentrations are required to completely inhibit the formation of toxic protein particles in Alzheimer’s, Parkinson’s, and other disorders.

To address this limitation, a team of researchers led by Rensselaer Professor Peter Tessier has developed a new process for creating antibodies that potently inhibit formation of toxic protein particles. Conventional antibodies typically bind to one or two target proteins per antibody. Antibodies created using Tessier’s method, however, bind to 10 proteins per antibody. The increased potency enables the novel antibodies to prevent the formation of toxic protein particles at unusually low concentrations. This is an important step toward creating new therapeutic molecules for preventing diseases such as Alzheimer’s and Parkinson’s.

“It is extremely difficult to get antibodies into the brain. Less than 5 percent of an injection of antibodies into a patient’s blood stream will enter the brain. Therefore, we need to make antibodies as potent as possible so the small fraction that does enter the brain will completely prevent formation of toxic protein particles linked to Alzheimer’s and Parkinson’s disease,” said Tessier, assistant professor in the Howard P. Isermann Department of Chemical and Biological Engineering at Rensselaer. “Our strategy for designing antibody inhibitors exploits the same molecular interactions that cause toxic particle formation, and the resulting antibodies are more potent inhibitors than antibodies generated by the immune system.”

Results of the new study, titled “Rational design of potent domain antibody inhibitors of amyloid fibril assembly,” were published online last week by the journal Proceedings of the National Academy of Sciences (PNAS). The study may be viewed at: http://www.pnas.org/content/early/2012/11/14/1208797109.abstract

This research was conducted in the laboratories of the Center for Biotechnology and Interdisciplinary Studies at Rensselaer.

Tessier’s research represents a new way of generating therapeutic antibodies. Currently, most antibodies are obtained by exploiting the immune system of rodents. Mice are injected with a target protein, for example the Alzheimer’s protein, and the animal’s immune system generates an antibody specific for the target protein. Tessier’s method is radically different as it relies on rational design approaches to create antibodies based on properties of the target proteins.

Along with Tessier, co-authors of the paper are Rensselaer graduate students Ali Reza Ladiwala, Moumita Bhattacharya, Joseph Perchiaccaa; Ping Cao and Daniel Raleigh of the Department of Chemistry at Stony Brook University; Andisheh Abedini and Ann Marie Schmidt of the Diabetes Research Program at New York University School of Medicine; and Jobin Varkey and Ralf Langen of the Zilkha Neurogenetic Institute at the University of Southern California, Los Angeles.

This study was funded with support from the American Health Assistance Foundation, the National Science Foundation, the Pew Charitable Trust, and the National Institutes of Health.

For more information on Tessier and his research at Rensselaer, visit:

• Tessier Lab Website
http://www.rpi.edu/~tessip
• Researchers Design Alzheimer’s Antibodies
http://news.rpi.edu/update.do?artcenterkey=2959
• Research From Rensselaer Professor Offers Clues to Alzheimer’s Disease
http://news.rpi.edu/update.do?artcenterkey=2743
• Rensselaer Professor Peter M. Tessier Named Pew Scholar
http://news.rpi.edu/update.do?artcenterkey=2740
• Rensselaer Professor Peter Tessier Receives NSF CAREER Award
http://news.rpi.edu/update.do?artcenterkey=2693
Contact
Michael Mullaney
Rensselaer Polytechnic Institute
Troy, NY
518-276-6161
mullam@rpi.edu
www.rpi.edu/news
Visit the Rensselaer research and discovery blog: http://approach.rpi.edu
Follow us on Twitter: www.twitter.com/RPInews

Michael Mullaney | Newswise
Further information:
http://www.rpi.edu/news

More articles from Life Sciences:

nachricht New Model of T Cell Activation
27.05.2016 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht Fungi – a promising source of chemical diversity
27.05.2016 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie - Hans-Knöll-Institut (HKI)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Worldwide Success of Tyrolean Wastewater Treatment Technology

A biological and energy-efficient process, developed and patented by the University of Innsbruck, converts nitrogen compounds in wastewater treatment facilities into harmless atmospheric nitrogen gas. This innovative technology is now being refined and marketed jointly with the United States’ DC Water and Sewer Authority (DC Water). The largest DEMON®-system in a wastewater treatment plant is currently being built in Washington, DC.

The DEMON®-system was developed and patented by the University of Innsbruck 11 years ago. Today this successful technology has been implemented in about 70...

Im Focus: Computational high-throughput screening finds hard magnets containing less rare earth elements

Permanent magnets are very important for technologies of the future like electromobility and renewable energy, and rare earth elements (REE) are necessary for their manufacture. The Fraunhofer Institute for Mechanics of Materials IWM in Freiburg, Germany, has now succeeded in identifying promising approaches and materials for new permanent magnets through use of an in-house simulation process based on high-throughput screening (HTS). The team was able to improve magnetic properties this way and at the same time replaced REE with elements that are less expensive and readily available. The results were published in the online technical journal “Scientific Reports”.

The starting point for IWM researchers Wolfgang Körner, Georg Krugel, and Christian Elsässer was a neodymium-iron-nitrogen compound based on a type of...

Im Focus: Atomic precision: technologies for the next-but-one generation of microchips

In the Beyond EUV project, the Fraunhofer Institutes for Laser Technology ILT in Aachen and for Applied Optics and Precision Engineering IOF in Jena are developing key technologies for the manufacture of a new generation of microchips using EUV radiation at a wavelength of 6.7 nm. The resulting structures are barely thicker than single atoms, and they make it possible to produce extremely integrated circuits for such items as wearables or mind-controlled prosthetic limbs.

In 1965 Gordon Moore formulated the law that came to be named after him, which states that the complexity of integrated circuits doubles every one to two...

Im Focus: Researchers demonstrate size quantization of Dirac fermions in graphene

Characterization of high-quality material reveals important details relevant to next generation nanoelectronic devices

Quantum mechanics is the field of physics governing the behavior of things on atomic scales, where things work very differently from our everyday world.

Im Focus: Graphene: A quantum of current

When current comes in discrete packages: Viennese scientists unravel the quantum properties of the carbon material graphene

In 2010 the Nobel Prize in physics was awarded for the discovery of the exceptional material graphene, which consists of a single layer of carbon atoms...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Networking 4.0: International Laser Technology Congress AKL’16 Shows New Ways of Cooperations

24.05.2016 | Event News

Challenges of rural labor markets

20.05.2016 | Event News

International expert meeting “Health Business Connect” in France

19.05.2016 | Event News

 
Latest News

11 million Euros for research into magnetic field sensors for medical diagnostics

27.05.2016 | Awards Funding

Fungi – a promising source of chemical diversity

27.05.2016 | Life Sciences

New Model of T Cell Activation

27.05.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>